Female Fertility and Pregnancy Rapid Test Market Report 2025

The female fertility and pregnancy rapid test market size has grown strongly in recent years. It will grow from $1.4 billion in 2024 to $1.49 billion in 2025 at a compound annual growth rate (CAGR) of 6.1%. The growth in the historic period can be attributed to increased awareness of reproductive health, delay in childbearing age, cultural and societal changes, rising maternal age, over-the-counter availability.

The female fertility and pregnancy rapid test market size is expected to see strong growth in the next few years. It will grow to $1.96 billion in 2029 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to personalized medicine approaches, rising interest in natural family planning, global fertility tourism, government initiatives for family planning, affordable healthcare initiatives. Major trends in the forecast period include digital health integration, telemedicine adoption, partnerships and collaborations in the healthcare industry, online retail channels for test kit sales, innovations in ovulation prediction tests.

The rising prevalence of gynecological disorders is anticipated to drive growth in the female fertility and pregnancy rapid test market. Gynecological disorders affect the female reproductive system and can include various conditions impacting the uterus, ovaries, vagina, and other related organs. Diagnosing fertility-related issues through tests can address infertility problems, reducing the impact of gynecological disorders. According to a July 2022 report by the National Library of Medicine, prevalent gynecological disorders encompass ailments such as uterine fibroids, spontaneous abortion, ovarian dysfunction, endometriosis, polycystic ovary syndrome, and dysmenorrhea. Hence, the market for female fertility and pregnancy rapid tests is experiencing growth due to the increasing occurrence of such disorders.

The rising healthcare expenditure is projected to fuel the growth of the female fertility and pregnancy rapid test market in the coming years. Healthcare expenditure refers to the total financial resources allocated for healthcare goods and services over a specific period, usually at a national or institutional level. Increased investment in healthcare can bolster research and development in reproductive health, leading to advancements in technology, enhanced accessibility to testing, and a more holistic approach to reproductive care, benefiting both individuals and healthcare systems. For example, according to the 2021-2030 National Health Expenditure (NHE) report released by the Centers for Medicare & Medicaid Services, a US-based federal agency, national health spending is expected to grow by an average of 5.1% annually between 2021 and 2030, reaching nearly $6.8 trillion. Additionally, Medicare spending is anticipated to increase at an annual rate of 7.2%, while Medicaid spending is projected to grow by 5.6% per year during this period. As a result, the rising healthcare expenditure is driving the expansion of the female fertility and pregnancy rapid test market.

A prevailing trend in the female fertility and pregnancy rapid test market is product innovation, particularly in the development of innovative test kits. Leading companies are focusing on creating novel solutions to fortify their market presence. For instance, in November 2022, Salignostics, an Israel-based research and development firm, introduced Salistick, a saliva-based pregnancy test. Salistick is a pioneering rapid saliva-based pregnancy test that offers improved user interface and high accuracy in detecting early pregnancy by identifying the pregnancy hormone (HCG) in saliva. The kit's technology allows users to collect saliva for testing, providing results in less than 10 minutes, offering convenience and quick detection of pregnancy using an innovative approach.

Major enterprises within the female fertility and pregnancy rapid test market are concentrating on innovative offerings, such as home fertility test kits, aimed at providing enhanced fertility status assessments within the comfort of one's home. A home fertility test kit refers to a device or kit designed for individuals to self-collect samples and analyze hormone levels or reproductive health indicators without visiting a medical facility. For example, in January 2022, Kindbody, a New York-based provider of fertility clinic networks and family-building benefits, introduced the Kind at Home fertility test. This test kit offers a comprehensive assessment of fertility status for both men and women, obtained conveniently from home through a straightforward finger prick. Within a few days, users receive their results and tailored recommendations accessible via the proprietary Kindbody patient platform.

In May 2022, Hertility, a UK-based women's health company, acquired Grip for an undisclosed sum. This acquisition aims to expand Hertility's hormone testing capabilities and strengthen its reproductive health services, allowing for more precise assessments and improved patient outcomes in fertility management. Grip, a Netherlands-based company, specializes in innovative solutions for hormone analysis and reproductive health.

Major companies operating in the female fertility and pregnancy rapid test market include Abbott Laboratories, Atlas Medical GmbH, bioMérieux SA, Church & Dwight Co. Inc., Quidel Corporation, Egens Group, Eurofins Scientific SE, Everlywell Inc., Genea Pty Limited, Geratherm Medical AG, SA Scientific Ltd., Artron Laboratories Inc., PRIMA Lab SA, The Procter & Gamble Company, Alere Inc., Prestige Brands Holdings Inc., SPD Swiss Precision Diagnostics GmbH, Fairhaven Health LLC, Fertility Focus Limited, HiLin Life Products Inc., Inverness Medical Innovations Inc., UEBE Medical GmbH, Wondfo Biotech Co. Ltd.

North America was the largest region in the female fertility and pregnancy rapid test market in 2024. The regions covered in the female fertility and pregnancy rapid test market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the female fertility and pregnancy rapid test market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The female fertility and pregnancy rapid tests involve methods for testing fertility and pregnancy in women, utilizing drugstore-bought urine tests and blood tests conducted at a doctor's office. These rapid test kits offer a straightforward and user-friendly solution for fertility testing, aiming to detect ovulation and diagnose infertility in females.

The primary products in the female fertility and pregnancy rapid tests category include fertility rapid test kits and pregnancy rapid test kits. Fertility rapid tests are in vitro diagnostic tools designed for the qualitative identification and assessment of pregnancy, fertility cycles, ovulation, and sperm counts within minutes. These devices come in various forms, including digital devices and line-indicator devices, and can be utilized for tests such as FSH urine test, LH urine test, HCG blood testing, and HCG urine testing. These kits are available through different distribution channels, including hospitals, retail outlets, and online platforms.

The female fertility and pregnancy rapid test market research report are one of a series of new reports that provides female fertility and pregnancy rapid test market statistics, including female fertility and pregnancy rapid test industry global market size, regional shares, competitors with a female fertility and pregnancy rapid test market share, detailed female fertility and pregnancy rapid test market segments, market trends and opportunities, and any further data you may need to thrive in the female fertility and pregnancy rapid test industry. This female fertility and pregnancy rapid test market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The female fertility and pregnancy rapid test market consists of sales of urine and blood test kits used to detect female pregnancy and fertility. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.